P783: Symptom Improvement of ulceRative colitis after an Injection dose of Ustekinumab in Japanese clinical practice, measured using patient-reported outcomes (SIRIUS) study, Interim AnalysisECCO’23 CopenhagenYear: 2023
Authors: Matsuoka, K.(1)*;Katsumasa, N.(2);Murata, Y.(2);Hisamatsu, T.(3);
(1)Toho University Sakura Medical Center, Division of Gastroenterology and Hepatology- Department of Internal Medicine, Sakura-city- Chiba, Japan;(2)Janssen Pharmaceutical K.K., Medical Affairs Division, Chiyoda-ku- Tokyo, Japan;(3)Kyorin University School of Medicine, Department of Gastroenterology and Hepatology, Mitaka-city- Tokyo, Japan;SIRIUS study group
P784: Real-world use and 6-month effectiveness of vedolizumab subcutaneous in IBD patients: results of the VEDO-IBD studyECCO’23 CopenhagenYear: 2023
Authors: Plachta-Danielzik, S.(1);Bokemeyer, B.(1,2,3)*;Efken, P.(4);Mohl, W.(5);Hoffstadt, M.(6);Krause, T.(7);Schweitzer, A.(8);Schnoy, E.(9);Ehehalt, R.(10);Trentmann, L.(11);Teich, N.(12);Atreya, R.(13);Franzenburg, S.(1);Hartmann, P.(4);Wenske, T.(1);Schreiber, S.(1,3);
(1)Competence network IBD, Study department, Kiel, Germany;(2)Interdisciplinary Crohn Colitis Centre Minden, Crohn Colitis Centre, Minden, Germany;(3)University Hospital Schleswig-Holstein- Campus Kiel, Clinic of General Internal Medicine I, Kiel, Germany;(4)Gastroenterology Practice Minden, Practice, Minden, Germany;(5)Center for Gastroenterology Saar MVZ, Practice, Saarbruecken, Germany;(6)Gastroenterology Practice Iserlohn, Practice, Iserlohn, Germany;(7)Gastroenterology Practice Kassel, Practice, Kassel, Germany;(8)Gastroenterology Practice Muenster, Practice, Muenster, Germany;(9)University Hospital Augsburg, III. medical clinic, Augsburg, Germany;(10)Gastroenterology Practice Heidelberg, Practice, Heidelberg, Germany;(11)Gastroenterology Practice Bremen, Practice, Bremen, Germany;(12)Gastroenterology Practice Leipzig, Practice, Leipzig, Germany;(13)Friedrich-Alexander-University Erlangen-Nuernberg, Medical Clinic 1, Erlangen, Germany;
P785: A retrospective cohort study on vedolizumab trough levels in Crohn's disease patientsECCO’23 CopenhagenYear: 2023
Authors: Pokryszka, J.(1)*;Stadlmann, M.(2);Primas, C.(3);Gerold, N.(3);Reinisch, S.(3);
(1)Department of Gastroenterology and Hepatology- Medical University of Vienna- Vienna- Austria, Department of Gastroenterology and Hepatology, Vienna, Austria;(2)Medical University of Viena, Department of Gastroenterology and Hepatology, Vienna, Austria;(3)Medical University of Vienna, Department of Gastroenterology and Hepatology, Vienna, Austria;
P786: Induction of endoscopic response, remission and ulcer-free endoscopy with upadacitinib is associated with improved clinical outcomes in patients with Crohn's diseaseECCO’23 CopenhagenYear: 2023
Authors: Panés, J.(1)*;Louis, E.(2);Bossuyt, P.(3);Joshi, N.(4);Lee, W.J.(4);Lacerda, A.(4);Remple, V.(4);Xuan, S.(4);Loftus Jr. , E.V.(5);
(1)Hospital Clinic Barcelona- IDIPABS- CIBERehd, n/a, Barcelona, Spain;(2)University Hospital CHU of Liège, n/a, Liège, Belgium;(3)Imelda General Hospital, Imelda GI Clinical Research Centre, Bonheiden, Belgium;(4)AbbVie Inc., n/a, Chicago, United States;(5)Mayo Clinic College of Medicine and Science, n/a, Rochester, United States;
P787: Subcutaneous infliximab in IBD patients with previous immunogenic failure of intravenous infliximabECCO’23 CopenhagenYear: 2023
Authors: Husman, J.(1)*;Matthes, K.(1);Gilger, M.(1);Arsova, M.(1);Schmidt, A.(1);Hampe, J.(1);Zeißig, S.(1);Schmelz, R.(1);
(1)University Hospital Dresden- Technische Universität TU Dresden, Department of Medicine I, Dresden, Germany;
P788: Endoscopic management of patients with high-risk colorectal colitis-associated neoplasia: a Delphi studyECCO’23 CopenhagenYear: 2023
Authors: Bak, M.(1,2)*;Albéniz, E.(3);East, J.(4,5);Coelho-Prabhu, N.(6);Suzuki, N.(7);Saito, Y.(8);Matsumoto, T.(9);Banerjee, R.(10);Kaminski, M.(11);Kiesslich, R.(12);Coron, E.(13);de Vries, A.(14);van der Woude, C.J.(14);Bisschops, R.(15);Hart, A.(16);Itzkowitz, S.(17);Pioche, M.(18);Moons, L.(1);Oldenburg, B.(1);
(1)University Medical Center Utrecht, Department of Gastroenterology and Hepatology, Utrecht, The Netherlands;(2)Erasmus University Medical Center Rotterdam, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands;(3)Hospital Universitario de Navarra HUN Navarrabiomed- Universidad Pública de Navarra UPNA- IdiSNA, Endoscopy Unit- Gastroenterology Department, Pamplona, Spain;(4)John Radcliffe Hospital- University of Oxford- and Oxford NIHR Biomedical Research Centre, Translational Gastroenterology Unit, Oxford, United Kingdom;(5)Mayo Clinic Healthcare, Division of Gastroenterology and Hepatology, London, United Kingdom;(6)Mayo Clinic, Department of Gastroenterology and Hepatology, Rochester- Minnesota, United States;(7)St Mark's Hospital and Academic Institute, Wolfson Unit for Endoscopy, Lodnon, United Kingdom;(8)National Cancer Center Hospital, Endoscopy Division, Tokyo, Japan;(9)School of Medicine- Iwate Medical University, Division of Gastroenterology- Department of Internal Medicine, Morioka- Iwate, Japan;(10)Asian Institute of Gastroenterology, Inflammatory Bowel Disease Center, Hyderabad, India;(11)Medical Center for Postgraduate Education, Department of Gastroenterology- Hepatology and Oncology, Warsaw, Poland;(12)Helios Dr Horst Schmidt Kliniken Wiesbaden, Medical Director, Wiesbaden, Germany;(13)University Hospital of Geneva HUG, Department of Gastroenterology and Hepatology, Genève, Switzerland;(14)Erasmus University Medical Center, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands;(15)University Hospitals Leuven- TARGID- KU Leuven-, Department of Gastroenterology and Hepatology, Leuven, Belgium;(16)St Mark's Hospital and Academic Institute, Department of Gastroenterology, London, United Kingdom;(17)Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York- New York, United States;(18)Edouard Herriot Hospital- Hospices Civils de Lyon, Endoscopy and Gastroenterology Unit, Lyon, France;
P789: Inflammatory Bowel Disease subgroups identified by longitudinal faecal calprotectin profiles: A 10-year retrospective analysis of the Lothian IBD RegistryECCO’23 CopenhagenYear: 2023
Authors: Constantine-Cooke, N.(1,2)*;Monterrubio-Gómez, K.(1);Plevris, N.(3);Derikx, L.A.A.P.(4);Lyons, M.(3);Jenkinson, P.W.(3);Gros, B.(3);Jones, G.R.(5);Vallejos, C.A.(1,6);Lees, C.W.(2,3);
(1)University of Edinburgh, MRC Human Genetics Unit, Edinburgh, United Kingdom;(2)University of Edinburgh, Centre for Genomic and Experimental Medicine, Edinburgh, United Kingdom;(3)Edinburgh IBD Unit, Edinburgh IBD Unit, Edinburgh, United Kingdom;(4)Radboud University Medical Centre, Gastroenterology and Hepatology, Nijmegen, The Netherlands;(5)University of Edinburgh, Centre for Inflammation Research, Edinburgh, United Kingdom;(6)The Alan Turing Institute, The Alan Turing Institute, London, United Kingdom;
P792: Pharmacokinetics and clinical evaluation of vedolizumab based on real-life routine monitoring data in IBD patientsECCO’23 CopenhagenYear: 2023
Authors: Markovic, S.(1)*;Kralj, D.(1);Odanovic, O.(1);Homšek, A.(2);Kalaba, A.(1);Svorcan, P.(1);Vučićević, K.(2);
(1)University Hospital Medical Center "Zvezdara", Gastroenterology and Hepatology Department, Belgrade, Serbia;(2)Faculty of Pharmacy – University of Belgrade- Republic of Serbia, Department of Pharmacokinetics and Clinical Pharmacy, Belgrade, Serbia;
P793: Infliximab and prevention of colectomy in acute severe ulcerative colitis: an individual patient data meta-analysisECCO’23 CopenhagenYear: 2023
Authors: Wang, Z.(1)*;Afif , W.(2);Hanžel, J.(3,4);Kobayashi , T.(5);Papamichail , K.(6);Roblin , X.(7);Peyrin-Biroulet , L.(8);Vermeire , S.(9);Dreesen, E.(1);
(1)KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium;(2)McGill University, Department of Medicine, Montreal, Canada;(3)University Medical Centre Ljubljana, Department of Gastroenterology, Ljubljana, Slovenia;(4)University of Ljubljana, Department of Internal Medicine, Ljubljana, Slovenia;(5)Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan;(6)Beth Israel Deaconess Medical Center, Division of Gastroenterology, Boston, United States;(7)University Hospital of Saint Etienne, Department of Gastroenterology, Saint Etienne, France;(8)Nancy University Hospital, Department of Gastroenterology, Nancy, France;(9)KU Leuven, Department of Chronic Diseases and Metabolism, Leuven, Belgium;
P794: Effectiveness of administering zinc acetate hydrate to patients with inflammatory bowel disease and zinc deficiency: a retrospective observational two-center studyECCO’23 CopenhagenYear: 2023
Authors: Sakurai, K.(1)*;Katsurada, T.(1);Aoyama, K.(1);Fukushima, S.(1);Onishi, R.(1);Yagisawa, K.(2);Nishimura, H.(2);Ito, T.(2);Furukawa, S.(2);Maemoto, A.(2);Sakamoto, N.(1);
(1)Hokkaido University Hospital, Department of Gastroenterology and Hepatology, Sapporo City-Hokkaido, Japan;(2)Sapporo Higashi Tokushukai Hospital, Inflammatory Bowel Disease Center, Sapporo City-Hokkaido, Japan;
P795: Impact of anxiety and depression on inflammatory bowel disease patientsECCO’23 CopenhagenYear: 2023
Authors: SinaDr., M.(1)*;Pemaj, X.(1);Djegsi, A.(1);Telaku, S.(2);Osmanaj, D.(1);Babameto, A.(1);Prifti, S.(1);
(1)University Hospital Center Mother Theresa, Internal Medicine/ Gastroenterology, Tirana, Albania;(2)UBD, Gastroenterology, Pristina, Kosovo;
P796: Effectiveness and safety of ustekinumab for patients with ulcerative colitis: A single-centre retrospective studyECCO’23 CopenhagenYear: 2023
Authors: Kimura, M.(1)*;Shimizu, M.(1);Shirai, M.(1);Sakaguchi, Y.(1);Kobayashi, K.(1);Iruya, R.(1);Seki, S.(1);Naitou, D.(1);Nishimiya, T.(1);Oouchi, Y.(1);Shibamoto, M.(1);Iwashita, H.(1);Miyamura, M.(1);Kikuchi, H.(1);Yamada, A.(1);Nakamura, K.(1);Matsuoka, K.(1);
(1)Toho University Sakura Medical Center, Gastroenterology, Sakura, Japan;
P797: Self-reported efficacy and safety of infliximab and adalimumab biosimilars after non-medical switch in patients with Inflammatory Bowel Disease: Results of a multicenter surveyECCO’23 CopenhagenYear: 2023
Authors: Bikar, A.(1);Farkas, N.(2);Resál, T.(3);Szepes, Z.(3);Klaudia, F.(3);Vincze, Á.(1);Miheller, P.(4);Molnár , T.(3);Sarlós, P.(1)*;
(1)Medical School- University of Pécs, Division of Gastroenterology- First Department of Medicine, Pécs, Hungary;(2)Medical School- University of Pécs, Institute for Translational Medicine-, Pécs, Hungary;(3)Faculty of Medicine- University of Szeged, First Department of Medicine, Szeged, Hungary;(4)Semmelweis University- Budapest, Department of Surgery- Transplantation and Gastroenterology, Budapest, Hungary;
P798: Understanding anti-TNF treatment failure: mechanisms and management of loss of response to anti-TNF therapy, three-year data from the PANTS study.ECCO’23 CopenhagenYear: 2023
Authors: Chanchlani, N.(1)*;Lin, S.(1);Hamilton, B.(1);Bewshea, C.(1);Thomas, A.(1);Smith, R.(1);Roberts, C.(1);Nice, R.(2);McDonald, T.J.(2);Goodhand, J.R.(1);Ahmad, T.(1);Kennedy, N.A.(1);
(1)Exeter IBD Pharmacogenetics, Gastroenterology, Exeter, United Kingdom;(2)Exeter IBD Pharmacogenetics, Biochemistry, Exeter, United Kingdom;PANTS Consortium
P800: Upadacitinib is effective and safe for Crohn's Disease: prospective real-world experienceECCO’23 CopenhagenYear: 2023
Authors: Friedberg, S.(1)*;Choi, D.(1);Hunold, T.(1);Choi, N.K.(1);Garcia, N.M.(1);Picker, E.A.(1);Cohen, N.A.(1);Cohen, R.D.(1);Dalal, S.R.(1);Pekow, J.(1);Sakuraba, A.(1);Cleveland, N.K.(1);Rubin, D.T.(1);
(1)University of Chicago, Inflammatory Bowel Disease Center, Chicago, United States;
P801: Maintenance phase effectiveness and persistence after two years in biologic-naïve ulcerative colitis patients treated with vedolizumab or anti-TNF (VEDO-IBD-study)ECCO’23 CopenhagenYear: 2023
Authors: Plachta-Danielzik, S.(1);Bokemeyer, B.(1,2,3)*;Efken, P.(4);Mohl, W.(5);Krause, T.(6);Hoffstadt, M.(7);Ehehalt, R.(8);Trentmann, L.(9);Schweitzer, A.(10);Jessen, P.(11);Franzenburg, S.(1);Hartmann, P.(4);di Giuseppe, R.(1);Schreiber, S.(1,3);
(1)Competence network IBD, Study department, Kiel, Germany;(2)Interdisciplinary Crohn Colitis Centre Minden, Crohn Colitis Centre, Minden, Germany;(3)University Hospital Schleswig-Holstein- Campus Kiel, Clinic of General Internal Medicine I, Kiel, Germany;(4)Gastroenterology Practice Minden, Practice, Minden, Germany;(5)Center for Gastroenterology Saar MVZ, Practice, Saarbruecken, Germany;(6)Gastroenterology Practice Kassel, Practice, Kassel, Germany;(7)Gastroenterology Practice Iserlohn, Practice, Iserlohn, Germany;(8)Gastroenterology Practice Heidelberg, Practice, Heidelberg, Germany;(9)Gastroenterology Practice Bremen, Practice, Bremen, Germany;(10)Gastroenterology Practice Muenster, Practice, Muenster, Germany;(11)Gastroenterology Practice Altenholz, Practice, Altenholz, Germany;
P802: Relationships between validated clinical, endoscopic and histological indices in ulcerative colitisECCO’23 CopenhagenYear: 2023
Authors: Walsh, A.(1);Kormilitzin, A.(1);Friedrich, M.(1);Pakpoor, J.(1);HosackMBChB MSc MRCP, T.(1)*;Matini, L.(1);Kantschuster, R.(1);Sharda, A.(1);Dunbar, G.(1);Cheung, V.T.F.(1);Ambrose, T.(1);Brain, A.O.(1);Palmer, R.(1);Satsangi, J.(1);Travis, S.P.L.(1);
(1)University of Oxford, Translational Gastroenterology Unit- Biomedical Research Centre- Mathematical Institute and Kennedy Institute, Oxford, United Kingdom;
